A new experimental test may be able to predict if a patient’s cancer will return after being treated with immunotherapy. The test looks for specific changes in the tumor that indicate the cancer is preparing to come back.
If the test is accurate, it could be used to help patients and their doctors make treatment decisions. It could also help researchers developing new treatments for cancer.
The test is still in the early stages of development and has not been proven to work yet. However, the results so far are promising.
Cancer immunotherapy is a treatment that uses the body’s immune system to fight cancer. It is sometimes called biological therapy or biotherapy.
Immunotherapy is a type of cancer treatment that helps the body’s immune system kill cancer cells. The immune system is a complex system that helps the body fight infection and disease.
Cancer immunotherapy drugs are made from living cells or parts of living cells. They work by helping the immune system work better against cancer.
Cancer immunotherapy can be used alone or with other cancer treatments, such as surgery, chemotherapy, or radiation therapy.
Immunotherapy is a newer type of cancer treatment. It is still being studied in clinical trials and is not yet widely available.
A new test could help doctors improve immunotherapy treatments and prevent relapses in cancer patients, British researchers say.
The test uses a small sample of a patient’s tumor to predict whether they will respond to immunotherapy and whether the cancer is likely to return.
The findings, published in the journal Nature Medicine, could lead to more personalized and effective treatments for cancer patients.
Immunotherapy is a type of cancer treatment that boosts the body’s immune system to fight the disease. It has shown promise in treating a range of cancers, but only works for a small number of patients.
The new test, developed by scientists at the University of Southampton, could help doctors select patients who are most likely to benefit from immunotherapy.
It could also help doctors identify patients who are at risk of the cancer returning after treatment.
The test works by analyzing the genetic makeup of a patient’s tumor. It looks for changes in the DNA that make the tumor more likely to respond to immunotherapy.
It also looks for changes that make the tumor more likely to grow back after treatment.
The test is still in the early stages of development, and more research is needed to confirm its accuracy.
But the scientists say it has the potential to transform the way immunotherapy is used to treat cancer.
Professor Nigel Minton, who led the research, said: “This is a hugely exciting development that has the potential to change the way we use immunotherapy to treat cancer.”
“If we can identify which patients are most likely to benefit from immunotherapy, we can tailor treatments to them and improve outcomes.”
The test could also help doctors choose the best time to start immunotherapy, to maximise the chances of the treatment being successful.
Dr. Katia Georgiou, who co-led the research, said: “This test could also be used to monitor patients during treatment, to see if the cancer is likely to return.”
“This would allow us to intervene early to prevent relapses and improve outcomes for patients.”